In a recent study, researchers at WashU Medicine found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer’s disease who received lecanemab infusions at the Memory Diagnostic Center at WashU Medicine.

The National Institutes of Health (NIH) has awarded a $15.3 million grant to help researchers diagnose the progressive brain disease chronic traumatic encephalopathy (CTE) in the living. The funds, from the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, will form a consortium of top academic research centers, led by the Boston University CTE Center, known as “The DIAGNOSE CTE Research Project-II.” The study will examine new potential biomarkers using blood and brain imaging to help doctors accurately diagnose CTE in living patients. It will also help doctors learn how to differentiate CTE in the clinic from similar diseases like Alzheimer’s.